hVIVO plc Board Changes (7143V)
20 April 2016 - 4:01PM
UK Regulatory
TIDMHVO
RNS Number : 7143V
hVIVO plc
20 April 2016
For immediate release 07:01: 20 April 2016
HVIVO PLC
("hVIVO" or the "Company")
BOARD CHANGES
hVIVO plc (AIM: HVO), the pioneer of human disease models, is
pleased to announce changes to its Board to support hVIVO's
continued growth and evolution. David Norwood, who was appointed
Chairman of the Board in 2011 and served in that capacity until
2014, will be retiring as a Non-Executive Director by rotation at
the Company's AGM on 23 May 2016 and not seeking reappointment.
Alison Fielding, who has served as a Non-Executive Director of
hVIVO since July 2014, will also be retiring at the Company's AGM.
Mark Warne joins the hVIVO Board as a Non-Executive Director with
immediate effect and which will be proposed for approval at the
Company's AGM.
Both David and Alison have provided invaluable guidance to hVIVO
since they joined. While David Norwood is retiring as a Director,
he will continue to support hVIVO as a strategic consultant. David
has played a pivotal role in crafting the hVIVO vision and business
strategy since 2011, along with providing stewardship as a
Director. In his new role as a consultant to hVIVO, he will
continue to support hVIVO in the development of our strategy and
investor relations. Alison has provided valuable experience
building high performance companies and has helped to steer hVIVO's
evolution into a more products-based organisation.
Mark brings a wealth of technology commercialisation experience
to help direct hVIVO through its next chapter of product
development and value creation. He is Head of IP Group plc's
Healthcare division, which at the end of December 2015 had
shareholdings in 31 companies valued at over GBP275 million. He
represents IP Group plc on the boards of a number of its portfolio
companies, both quoted and private. Mark has been at IP Group since
2008 and has extensive experience in building world-changing
healthcare businesses as well as in managing transactions including
portfolio company IPOs, financings and M&A.
Kym Denny, Chief Executive Officer, commented, "hVIVO is moving
quickly to broaden its platform and commercialise its discoveries.
The changes to our Board enable us to continue that momentum
forward. I would like to thank both Dave and Ali for helping hVIVO
make enormous strides on our journey to revolutionise drug
development, by putting humans at the heart of drug discovery. I
would like to welcome Mark Warne who will play an instrumental role
in guiding hVIVO's future commercialisation strategies."
Dr Mark Robert Warne, aged 40, is a director/ partner or has
been a director/ partner of the following companies/ partnerships
during the previous five years:
Current
Capsant Neurotechnologies Limited
Cronin Group plc
Crysalin Limited
Genomics plc
Oxford CADD Limited
Previous
Bristol Innovations Limited
Oxtox Limited
31 Howard Road Management Limited
Optimal Medicine Inc
OM France SARL
Dr Mark Warne holds 5,677 ordinary shares of 5p each in hVIVO
plc.
Save for the information disclosed above there is no other
information to be disclosed on Dr Mark Warne under Schedule 2(g) of
the AIM Rules.
For further information please contact:
hVIVO plc +44 207 756 1300
Kym Denny (CEO)
Graham Yeatman (Chief Financial & Business Officer)
Media Enquiries +44 203 021 3933 / +44 7854 979 420
Colin Paterson (Director of Marketing, Communication and PR)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
Notes to Editors:
hVIVO plc ("hVIVO") is a life sciences company pioneering a
technology platform of human disease models to accelerate drug
discovery and development in respiratory and infectious diseases,
including flu, RSV, asthma and common cold. hVIVO has
commercialised four disease models, successfully enrolled over
2,000 subjects and conducted over 40 product validation studies for
a wide range of industry, government and academic clients and
collaborators.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAAKCDNBBKBOQD
(END) Dow Jones Newswires
April 20, 2016 02:01 ET (06:01 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From Jul 2023 to Jul 2024